NCT05598775
Long-Term Safety Study of CTX0E03 in Subjects Who Completed PISCES III Study
Enrolling by Invitation
Not specifiedAges 35–75ObservationalReNeuron Limited
~9 participants
Updated 2023-03-31 on ClinicalTrials.gov
What's tested:Non Interventional long term safety follow up
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Long-term safety study is to follow up subjects treated with CTX0E03 DP
Measured over 4 Years
Conditions
Where it's being run
1 sites across 1 statesWest Virginia1
Study leadership
- Amy Miller, RPh, PharmD · PRINCIPAL_INVESTIGATOR · UBC
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Exclusion
None
What this trial measures
- Long-term safety study is to follow up subjects treated with CTX0E03 DP4 Years
Identify delayed oncological, neurological, and CTX0E03 DP-related adverse events and to monitor survival.